VKTX

VKTX

USD

Viking Therapeutics Inc. Common Stock

$34.630-2.110 (-5.743%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$36.740

高値

$38.000

安値

$34.615

出来高

3.77M

企業ファンダメンタルズ

時価総額

3.9B

業種

バイオテクノロジー

United States

取引統計

平均出来高

6.60M

取引所

NCM

通貨

USD

52週レンジ

安値 $18.92現在値 $34.630高値 $70.41

関連ニュース

Reuters

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

Metsera has become the obesity drug market's hottest ticket.

もっと見る
Metsera the US obesity biotech at centre of Novo, Pfizer bidding war
Analyst Upgrades

Canaccord Genuity Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $106

Canaccord Genuity analyst Edward Nash initiates coverage on Viking Therapeutics with a Buy rating and announces Price Target of $106.

もっと見る
Canaccord Genuity Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $106
Analyst Upgrades

JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $75

JP Morgan analyst Hardik Parikh maintains Viking Therapeutics with a Overweight and lowers the price target from $80 to $75.

もっと見る
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $75
Analyst Upgrades

Morgan Stanley Maintains Overweight on Viking Therapeutics, Raises Price Target to $102

Morgan Stanley analyst Michael Ulz maintains Viking Therapeutics with a Overweight and raises the price target from $98 to $102.

もっと見る
Morgan Stanley Maintains Overweight on Viking Therapeutics, Raises Price Target to $102
PR Newswire

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...

もっと見る
Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
PR Newswire

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...